<DOC>
	<DOCNO>NCT01289132</DOCNO>
	<brief_summary>The purpose study evaluate dose-response relationship azilsartan , daily ( QD ) participant mild moderate uncomplicated essential hypertension .</brief_summary>
	<brief_title>Efficacy Safety Azilsartan Participants With Mild Moderate Uncomplicated Essential Hypertension</brief_title>
	<detailed_description>Hypertension know cause multiple organ damage combine blood pressure also hemodynamics , endocrinological/metabolic abnormality genetic factor . This become medically medical-economically significant problem Japan The significance early treatment hypertension long-term control blood pressure increase year year . Takeda Pharmaceutical Company Limited invent TAK-536 ( azilsartan ) , angiotensin II receptor blocker decrease blood pressure . This study investigate efficacy safety azilsartan use candesartan cilexetil , widely use antihypertensive drug , reference control .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Has mild moderate uncomplicated essential hypertension . Has sit diastolic blood pressure 95 &lt; 110 mmHg sit systolic blood pressure 150 &lt; 180 mmHg placebo runin period ( Week 2 ) randomization visit . Has cardiovascular disease symptom Has treat 3 different antihypertensive within 27 day prior placebo runin period . Has significant hepatic disorder , hyperkalemia , malignant tumor significant renal impairment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>